{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116329","form_type":"8-K","ticker":null,"cik":"0000827871","company_name":"EAGLE PHARMACEUTICALS, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.117957+00:00","generated_at":"2026-05-30T02:32:12.307541+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO effective Nov 11, 2024","bullets":["Christopher Krawtschuk named CFO, effective Nov 11; Steven Ratoff steps down as interim CFO, remains director.","Krawtschuk previously CFO/treasurer at bluebird bio, CFO at Jubilant Pharma, U.S. CFO at Morphosys.","Offer letter: $525k base salary, 50% target bonus, $150k signing bonus, 100k performance-vesting RSUs tied to listing and SEC filings.","Shares trade on OTC Expert Market since Oct 4; 13,023,123 shares outstanding as of Oct 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116329","json":"https://secwatch.observer/filing/0001104659-24-116329.json","markdown":"https://secwatch.observer/filing/0001104659-24-116329.md","text":"https://secwatch.observer/filing/0001104659-24-116329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/tm2427095d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:32:12.307541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baabfbd52f","claim":"Steven Ratoff changed role as Interim Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..","evidence_excerpt":"In connection with Mr. Krawtschuk’s appoinment, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, Steven Ratoff, stepped down from serving in such capacities on the Effective Date and will remain as a director on the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d3c49e4d22","claim":"Christopher Krawtschuk was appointed as Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..","evidence_excerpt":"On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk to serve as the Company’s Chief Financial Officer, and designated Mr. Krawtschuk as its principal financial officer and principal accounting officer, each effective November 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}